Márkus Béla, Bajner Agnes, Csejtei András, Firisz Borbála, Hegedus Agnes, Kocsis Eszter, Kovács Beáta, Pintér Gábor, Tóth Csaba
Er- és Központi Szeptikus Sebészeti Osztály,
Magy Seb. 2006 Oct;59(5):375-82.
In addition to discussing effectiveness of breast cancer screening initiated within the National Public Health Programme, the problem of how to treat non-palpable, early invasive and in situ breast cancer (DCIS) is considered. The theoretical issue of the sentinel lymph node and its impact on biopsy practice have also been dealt with. In the authors' region, screening was introduced in 1999 and after a short break has been continued since 2002. Patient data of three periods, each of two years, each with ten years' interval (1982-1983, 1992-1993, 2002-2003) have been analysed. Changes in the number of surgical operations and tumour size, incidence of in situ cancer, lymph node involvement and distribution of types of surgery have been studied. Biopsy of the sentinel lymph node has been applied since May, 2003 (with 45 biopsies performed until 31 December, 2004). The number of persons participating in the screening programme has gradually increased, the number of surgical operations because of breast cancer increased from period to period. Size of the detected tumours has decreased, the percentage of non-palpable cases has been significant (445 surgical interventions during the years 2002-2004: surgery: 19%). The proportion of DCIS has increased to nearly four times as compared to data of years immediately preceding the era of screening (1993-1998: 11 cases, 2%; 1999-2004: 62 cases, 7.5%). Specificity of sentinel lymph node biopsy was 90%, with a sensitivity of 65%. The proportion of breast saving surgery has increased above 50%. The authors regard screening as successful, in their opinion, its benefits cannot be questioned, in spite of some controversial issues. As to the treatment of non-palpable, early invasive cancer, they underline the importance of preoperative evaluation--cytology, core biopsy--and establishing dignity. The issues of localisation--wire hook marking--and histological processing--large blocks--have also been dealt with. In spite of the fact that the risk for potential malignancy of DCIS lesions has not yet been fully clarified, adequate treatment is indicated; the authors take stand on the issues of indication for surgery, postoperative radiotherapy and use of Tamoxifen. Indications and contraindications of sentinel lymph node biopsy have been summed up.
除了讨论国家公共卫生项目中启动的乳腺癌筛查的有效性外,还考虑了如何治疗不可触及的早期浸润性和原位乳腺癌(导管原位癌)的问题。前哨淋巴结的理论问题及其对活检实践的影响也已得到探讨。在作者所在地区,1999年引入了筛查,经过短暂中断后,自2002年起继续进行。分析了三个时期、每个时期两年、间隔均为十年(1982 - 1983年、1992 - 1993年、2002 - 2003年)的患者数据。研究了手术操作数量和肿瘤大小的变化、原位癌的发病率、淋巴结受累情况以及手术类型的分布。自2003年5月起应用前哨淋巴结活检(截至2004年12月31日共进行了45次活检)。参与筛查项目的人数逐渐增加,因乳腺癌进行的手术操作数量逐期增加。检测到的肿瘤大小有所减小,不可触及病例的比例显著(2002 - 2004年期间有445例手术干预:手术:19%)。与筛查时代之前几年的数据相比,导管原位癌的比例增加到了近四倍(1993 - 1998年:11例,2%;1999 - 2004年:62例,7.5%)。前哨淋巴结活检的特异性为90%,敏感性为65%。保乳手术的比例已超过50%。作者认为筛查是成功的,尽管存在一些有争议的问题,但在他们看来,其益处不容置疑。关于不可触及的早期浸润性癌的治疗,他们强调术前评估——细胞学检查、粗针活检——以及确定病情的重要性。还探讨了定位——金属丝钩标记——和组织学处理——大组织块——的问题。尽管导管原位癌病变潜在恶性的风险尚未完全阐明,但仍需进行充分治疗;作者对手术指征、术后放疗和他莫昔芬的使用等问题表明了立场。总结了前哨淋巴结活检的适应证和禁忌证。